Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. downgraded their outlook for Rallybio (NasdaqGS:RLYB) from Buy to ...

H.C. Wainwright raised the firm’s price target on FTC Solar (FTCI) to $5 from $1.50 and keeps a Buy rating on the shares following the 1-for-10 ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for Ryvyl in a research report issued to clients and investors on Thursday, April 3rd. HC Wainwright analyst K. Dede ...

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Genmab (GMAB) to $37 from $50 and keeps a Buy rating on the ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.29, a high ...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall ...

On Thursday, H.C. Wainwright analyst Andrew Maldonado maintained a Buy rating and a $36.00 price target for Day One Biopharmaceuticals (NASDAQ:DAWN) shares, representing significant upside ...